Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Immunomic Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Immunomic Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Immunomic Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Immunomic Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Immunomic Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Immunomic Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Immunomic Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Immunomic Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Immunomic Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Immunomic Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Immunomic Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunomic Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Immunomic Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Immunomic Therapeutics, Inc. Snapshot 5 Immunomic Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Immunomic Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Immunomic Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Immunomic Therapeutics, Inc. - Pipeline Products Glance 14 Immunomic Therapeutics, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Immunomic Therapeutics, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Immunomic Therapeutics, Inc. - Drug Profiles 18 TriMix-DC Vaccine 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Cell Therapy for HIV 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 HIV-LAMP-Vax 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 JRC-LAMP-Vax 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 LAMP-pp65 Dendritic Cell Vaccine + anti-IL-2R Monoclonal Antibody 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 MC-LAMP-Vax 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Td+pp65 DC Vaccine 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ARA-LAMP-Vax 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 JCC-LAMP-Vax 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 LAMP + Antigen mRNA Vaccine 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Multi-LAMP-Vax 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Immunomic Therapeutics, Inc. - Pipeline Analysis 31 Immunomic Therapeutics, Inc. - Pipeline Products by Target 31 Immunomic Therapeutics, Inc. - Pipeline Products by Route of Administration 33 Immunomic Therapeutics, Inc. - Pipeline Products by Molecule Type 34 Immunomic Therapeutics, Inc. - Recent Pipeline Updates 35 Immunomic Therapeutics, Inc. - Locations And Subsidiaries 36 Head Office 36 Other Locations & Subsidiaries 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Immunomic Therapeutics, Inc., Key Information 5 Immunomic Therapeutics, Inc., Key Facts 5 Immunomic Therapeutics, Inc. - Pipeline by Indication, 2014 8 Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9 Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2014 11 Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2014 12 Immunomic Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 Immunomic Therapeutics, Inc. - Phase II, 2014 14 Immunomic Therapeutics, Inc. - Phase I, 2014 15 Immunomic Therapeutics, Inc. - Preclinical, 2014 16 Immunomic Therapeutics, Inc. - Discovery, 2014 17 Immunomic Therapeutics, Inc. - Pipeline by Target, 2014 32 Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2014 33 Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2014 34 Immunomic Therapeutics, Inc. - Recent Pipeline Updates, 2014 35 Immunomic Therapeutics, Inc., Other Locations 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.